SCHEMBL3401353

SCHEMBL3401353

CN(c1ccc(F)cc1)S(=O)(=O)Nc1ccc2nc(N[C@@H]3CCc4ccccc43)ccc2c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 6/20 0.41
MAPK14 Q16539 2/20 0.39
MAPT P10636 3/20 0.37
RXFP1 Q9HBX9 1/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GLP1R P43220 1/20 0.35
TP53 P04637 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
FADS1 O60427 1/20 0.34
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
NPC1 O15118 1/20 0.34
HPGDS O60760 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4105895 0.92 PFKFB3 (0.37) PFKFB3KDM4ELMNAALOX15TSHR
SCHEMBL4100057 0.91 FADS1 (0.41) PFKFB3MAPTKDM4ELMNAALOX15
SCHEMBL4106792 0.90 HPGDS (0.43) PFKFB3MAPTKDM4ELMNAALOX15
SCHEMBL3412817 0.88 SMN1; SMN2 (0.42) PFKFB3MAPTKDM4ELMNAALOX15
SCHEMBL4101413 0.86 FADS1 (0.46) PFKFB3MAPTKDM4ELMNAALOX15
SCHEMBL4100050 0.85 MAPT (0.43) PFKFB3MAPK14MAPTRXFP1KDM4E
SCHEMBL4097398 0.85 KDM4E (0.38) PFKFB3KDM4ELMNAALOX15TSHR
SCHEMBL4104986 0.83 LMNA (0.39) PFKFB3KDM4ELMNAALOX15TSHR
SCHEMBL4097503 0.82 MET (0.39) PFKFB3MAPTKDM4ELMNAALOX15
SCHEMBL3398554 0.82 NPC1 (0.52) PFKFB3MAPK14MAPTLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US claimed
EP-2252372-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-11-24 EP claimed
WO-2009109502-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO claimed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US claimed
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
EP-2252372-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-11-24 EP disclosed
WO-2009109502-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227583-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2B PFKFB3 3870/4885MAPK14 4542/4885MAPT 905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.